secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acrivon Therapeutics, Inc. (ACRV)
CIK:        0001781174
Form:       8-K
Filed at:   2023-03-13T23:59:59+00:00
Accession:  0001193125-23-068545
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acrivon reports $169.6M cash, runway into Q4 2024; ACR-368 OncoSignature enriches ORR to 47-58% in ovarian cancer
--------------------------------------------------------------------------------

- Cash and marketable securities $169.6M as of Dec 31, 2022 (preliminary, unaudited); projected runway into at least Q4 2024.
- ACR-368 OncoSignature test enriched ORR to 47% (NCI) and 58% (Lilly) in blinded studies of platinum-resistant ovarian cancer biopsies.
- Registrational-intent Phase 2 single-arm trials of ACR-368 monotherapy in OncoSignature-positive patients planned for ovarian, endometrial, bladder, and HPV SCC cancers.
- Internal WEE1 and PKMYT1 inhibitors advancing to IND-enabling studies in 2023.
- Past Phase 2 all-comer ORR for ACR-368 in platinum-resistant ovarian cancer was 12.1%; mDoR 5.6 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781174/000119312523068545/0001193125-23-068545-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781174/000119312523068545/d385129d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-068545

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer